Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05494762
Title Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
City of Hope National Medical Center Duarte California 91010 United States Details
Yale University, Yale Cancer Center New Haven Connecticut 06520 United States Details
Tennessee Oncology, Pllc Nashville Nashville Tennessee 37203 United States Details
Blacktown Cancer and Haematology Centre Blacktown New South Wales 2148 Australia Details
Icon Cancer Centre Kurralta Park Kurralta Park South Australia 5037 Australia Details
Monash Health Clayton Victoria 3168 Australia Details
Peter Maccallum Cancer Centre Melbourne Victoria 3000 Australia Details
The Alfred Hospital Melbourne Victoria 3004 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field